Figure 2
From: Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer
Multivariate analysis of cardiotoxicity associated with targeted therapy (OR odds ratio, CAD coronary artery disease; *P < 0.05).
Figure 2 | Scientific Reports
